Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 1:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 1:30 p.m. ET. Management will also engage in one-on-one meetings throughout the conference, which runs from June 8-10, 2022. The live webcast and archived recording of the chat will be accessible via the Phathom website for 90 days post-event. Phathom is focused on novel gastrointestinal treatments and has exclusive rights to vonoprazan for H. pylori infection and is awaiting FDA review for erosive esophagitis treatment.
Details
News Market Reaction – PHAT
The recorded move for PHAT in the trading session of this news was +0.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 p.m. ET.
Company management will also participate in one-on-one meetings during the conference which runs from June 8-10, 2022.
To access the live webcast and archived recording of the fireside chat, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Vonoprazan-based regimens are approved in the U.S. as part of a co-packaged product in combination with antibiotics for the treatment of H. pylori infection in adults, marketed as VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin). Phathom has a New Drug Application under review by the FDA for vonoprazan in erosive esophagitis (EE) and is studying the use of vonoprazan for the treatment of non-erosive reflux disease (NERD). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
INVESTOR & MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
ir@phathompharma.com
© 2022 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks or trademarks of Phathom Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.